Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 415149, 10 pages
http://dx.doi.org/10.1155/2015/415149
Review Article

Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?

1Institute of Genetics and Biophysics “Adriano Buzzati-Traverso”, National Research Council, Via Pietro Castellino 111, 80131 Naples, Italy
2DiST, Department of Science and Technology, “Parthenope” University of Naples, Centro Direzionale, Isola C4, 80143 Naples, Italy

Received 3 March 2015; Accepted 24 May 2015

Academic Editor: Todd Leff

Copyright © 2015 Carla Pollastro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. World Health Organization, Diabetes, World Health Organization, Geneva, Switzerland, 2015.
  3. A. Hattersley, J. Bruining, J. Shield, P. Njolstad, and K. C. Donaghue, “The diagnosis and management of monogenic diabetes in children and adolescents,” Pediatric Diabetes, vol. 10, no. 12, pp. 33–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. G. C. Mannino and G. Sesti, “Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data,” Molecular Diagnosis & Therapy, vol. 16, no. 5, pp. 285–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Becker, E. R. Pearson, and I. Tkáč, “Pharmacogenetics of oral antidiabetic drugs,” International Journal of Endocrinology, vol. 2013, Article ID 686315, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. K. Di Stefano and R. M. Watanabe, “Pharmacogenetics of anti-diabetes drugs,” Pharmaceuticals, vol. 3, no. 8, pp. 2610–2646, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. K. Billings and J. C. Florez, “The genetics of type 2 diabetes: what have we learned from GWAS?” Annals of the New York Academy of Sciences, vol. 1212, pp. 59–77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Wang, H. L. McLeod, and R. M. Weinshilboum, “Genomics and drug response,” The New England Journal of Medicine, vol. 364, no. 12, pp. 1144–1153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Costa, C. Angelini, I. De Feis, and A. Ciccodicola, “Uncovering the complexity of transcriptomes with RNA-Seq,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 853916, 19 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. W. F. Doolittle and C. Sapienza, “Selfish genes, the phenotype paradigm and genome evolution,” Nature, vol. 284, no. 5757, pp. 601–603, 1980. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Vella, “Pharmacogenetics for type 2 diabetes: practical considerations for study design,” Journal of Diabetes Science and Technology, vol. 3, no. 4, pp. 705–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. P. Kang, X. Yang, R. Chen et al., “Integration of disease-specific single nucleotide polymorphisms, expression quantitative trait loci and co-expression networks reveal novel candidate genes for type 2 diabetes,” Diabetologia, vol. 55, no. 8, pp. 2205–2213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Belsey and G. Krishnarajah, “Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis,” Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. P. L. Drury and T. Cundy, “Glycemic management of type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 367, no. 2, pp. 182–183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Rendell, “The role of sulphonylureas in the management of type 2 diabetes mellitus,” Drugs, vol. 64, no. 12, pp. 1339–1358, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. S.-L. Shyng and C. G. Nichols, “Octameric stoichiometry of the KATP channel complex,” Journal of General Physiology, vol. 110, no. 6, pp. 655–664, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. E. R. Pearson, I. Flechtner, P. R. Njølstad et al., “Switching from insulin to oral sulphonylureas in patients with diabetes due to Kir6.2 mutations,” The New England Journal of Medicine, vol. 355, no. 5, pp. 467–477, 2006. View at Google Scholar
  18. M. Rafiq, S. E. Flanagan, A.-M. Patch et al., “Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations,” Diabetes Care, vol. 31, no. 2, pp. 204–209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Sun, W. Yu, and C. Hu, “Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application,” BioMed Research International, vol. 2014, Article ID 926713, 15 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Javorsky, L. Klimcakova, Z. Schroner et al., “KCNJ11 gene E23K variant and therapeutic response to sulfonylureas,” European Journal of Internal Medicine, vol. 23, no. 3, pp. 245–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-Y. He, R. Zhang, X.-Y. Shao et al., “Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients,” Acta Pharmacologica Sinica, vol. 29, no. 8, pp. 983–989, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Shu, N. S. Sauter, F. T. Schulthess, A. V. Matveyenko, J. Oberholzer, and K. Maedler, “Transcription factor 7-like 2 regulates β-cell survival and function in human pancreatic islets,” Diabetes, vol. 57, no. 3, pp. 645–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Yi, P. L. Brubaker, and T. Jin, “TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β,” Journal of Biological Chemistry, vol. 280, no. 2, pp. 1457–1464, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. S. F. A. Grant, G. Thorleifsson, I. Reynisdottir et al., “Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes,” Nature Genetics, vol. 38, no. 3, pp. 320–323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Tong, Y. Lin, Y. Zhang, J. Yang, H. Liu, and B. Zhang, “Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis,” BMC Medical Genetics, vol. 10, article 15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. E. R. Pearson, L. A. Donnelly, C. Kimber et al., “Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study,” Diabetes, vol. 56, no. 8, pp. 2178–2182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Javorský, E. Babjaková, L. Klimčáková et al., “Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide,” International Journal of Endocrinology, vol. 2013, Article ID 374858, 5 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Kirchheiner, J. Brockmöller, I. Meineke et al., “Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers,” Clinical Pharmacology and Therapeutics, vol. 71, no. 4, pp. 286–296, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Kirchheiner, S. Bauer, I. Meineke et al., “Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers,” Pharmacogenetics, vol. 12, no. 2, pp. 101–109, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Zhou, L. Donnelly, L. Burch et al., “Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a go-DARTS study,” Clinical Pharmacology and Therapeutics, vol. 87, no. 1, pp. 52–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. L. Aquilante, “Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms,” Expert Review of Cardiovascular Therapy, vol. 8, no. 3, pp. 359–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. H.-D. Yoo, M.-S. Kim, H.-Y. Cho, and Y.-B. Lee, “Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects,” European Journal of Clinical Pharmacology, vol. 67, no. 9, pp. 889–898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Klen, V. Dolžan, and A. Janež, “CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients,” European Journal of Clinical Pharmacology, vol. 70, no. 4, pp. 421–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Almind, C. Bjorbaek, H. Vestergaard, T. Hansen, S. Echwald, and O. Pedersen, “Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus,” The Lancet, vol. 342, no. 8875, pp. 828–832, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. G. G. Graham, J. Punt, M. Arora et al., “Clinical pharmacokinetics of metformin,” Clinical Pharmacokinetics, vol. 50, no. 2, pp. 81–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Zhou, C. Bellenguez, C. C. A. Spencer et al., “Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes,” Nature Genetics, vol. 43, no. 2, pp. 117–120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. N. van Leeuwen, G. Nijpels, M. L. Becker et al., “A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts,” Diabetologia, vol. 55, no. 7, pp. 1971–1977, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. S. B. Montgomery, M. Sammeth, M. Gutierrez-Arcelus et al., “Transcriptome genetics using second generation sequencing in a Caucasian population,” Nature, vol. 464, no. 7289, pp. 773–777, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Battle, S. Mostafavi, X. Zhu et al., “Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals,” Genome Research, vol. 24, no. 1, pp. 14–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. T. Nies, H. Koepsell, S. Winter et al., “Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver,” Hepatology, vol. 50, no. 4, pp. 1227–1240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. M. H. Christensen, C. Brasch-Andersen, H. Green et al., “The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c,” Pharmacogenetics and Genomics, vol. 21, no. 12, pp. 837–850, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Takane, E. Shikata, K. Otsubo, S. Higuchi, and I. Ieiri, “Polymorphism in human organic cation transporters and metformin action,” Pharmacogenomics, vol. 9, no. 4, pp. 415–422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Agostini, E. Schoenmakers, C. Mitchell et al., “Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance,” Cell Metabolism, vol. 4, no. 4, pp. 303–311, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Costa, M. A. Gallo, F. Letizia, M. Aprile, A. Casamassimi, and A. Ciccodicola, “PPARG: gene expression regulation and next-generation sequencing for unsolved issues,” PPAR Research, vol. 2010, Article ID 409168, 17 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Aprile, M. R. Ambrosio, V. D'Esposito et al., “PPARG in human adipogenesis: differential contribution of canonical transcripts and dominant negative isoforms,” PPAR Research, vol. 2014, Article ID 537865, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Knouff and J. Auwerx, “Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology,” Endocrine Reviews, vol. 25, no. 6, pp. 899–918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Heikkinen, J. Auwerx, and C. A. Argmann, “PPARγ in human and mouse physiology,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 999–1013, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. W. He, “PPARγ2Pro12Ala polymorphism and human health,” PPAR Research, vol. 2009, Article ID 849538, 15 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Ciccodicola, V. Costa, A. Casamassimi et al., “Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in italy,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 126917, 7 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. H. N. Gouda, G. S. Sagoo, A.-H. Harding, J. Yates, M. S. Sandhu, and J. P. T. Higgins, “The association between the peroxisome proliferator-activated receptor-γ2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis,” American Journal of Epidemiology, vol. 171, no. 6, pp. 645–655, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Zeggini, J. R. C. Parkinson, S. Halford et al., “Examining the relationships between the Pro12Ala variant in PPARG and type 2 diabetes-related traits in UK samples,” Diabetic Medicine, vol. 22, no. 12, pp. 1696–1700, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Hara, T. Okada, K. Tobe et al., “The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes,” Biochemical and Biophysical Research Communications, vol. 271, no. 1, pp. 212–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. V. I. Lindi, M. I. J. Uusitupa, J. Lindström et al., “Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study,” Diabetes, vol. 51, no. 8, pp. 2581–2586, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. J. C. Florez, K. A. Jablonski, M. W. Sun et al., “Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 4, pp. 1502–1509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. M.-C. Hsieh, K.-D. Lin, K.-J. Tien et al., “Common polymorphisms of the peroxisome proliferator-activated receptor-γ (Pro12Ala) and peroxisome proliferator-activated receptor-γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus,” Metabolism: Clinical and Experimental, vol. 59, no. 8, pp. 1139–1144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. E. S. Kang, S. Y. Park, H. J. Kim, and et al, “Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes,” Clinical Pharmacology and Therapeutics, vol. 78, no. 2, pp. 202–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Blüher, G. Lübben, and R. Paschke, “Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes,” Diabetes Care, vol. 26, no. 3, pp. 825–831, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Taylor and F. D. R. Hobbs, “Type 2 diabetes, thiazolidinediones, and cardiovascular risk,” The British Journal of General Practice, vol. 59, no. 564, pp. 520–524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. S. B. Montgomery and E. T. Dermitzakis, “From expression QTLs to personalized transcriptomics,” Nature Reviews Genetics, vol. 12, no. 4, pp. 277–282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. V. Costa, M. Aprile, R. Esposito, and A. Ciccodicola, “RNA-Seq and human complex diseases: recent accomplishments and future perspectives,” European Journal of Human Genetics, vol. 21, no. 2, pp. 134–142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. N. K. Yadav, P. Shukla, A. Omer, S. Pareek, and R. K. Singh, “Next generation sequencing: potential and application in drug discovery,” The Scientific World Journal, vol. 2014, Article ID 802437, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. M. L. Metzker, “Emerging technologies in DNA sequencing,” Genome Research, vol. 15, no. 12, pp. 1767–1776, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. R. P. Kandpal, H. K. Rajasimha, M. J. Brooks et al., “Transcriptome analysis using next generation sequencing reveals molecular signatures of diabetic retinopathy and efficacy of candidate drugs,” Molecular Vision, vol. 18, pp. 1123–1146, 2012. View at Google Scholar · View at Scopus
  65. D. L. Eizirik, M. Sammeth, T. Bouckenooghe et al., “The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines,” PLoS Genetics, vol. 8, no. 3, Article ID e1002552, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. E. P. Brennan, M. J. Morine, D. W. Walsh et al., “Next-generation sequencing identifies TGF-β1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy,” Biochimica et Biophysica Acta, vol. 1822, no. 4, pp. 589–599, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Marguerat, B. T. Wilhelm, and J. Bähler, “Next-generation sequencing: applications beyond Genomes,” Biochemical Society Transactions, vol. 36, no. 5, pp. 1091–1096, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Sultan, M. H. Schulz, H. Richard et al., “A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome,” Science, vol. 321, no. 5891, pp. 956–960, 2008. View at Publisher · View at Google Scholar · View at Scopus